Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/172293
Title: Documento de la Sociedad Española de Hipertensión-Liga Española para la Lucha contra la Hipertensión Arterial (SEH-LELHA) sobre las guías ACC/AHA 2017 de hipertensión arterial
Author: Gijón-Conde, T.
Gorostidi, M.
Camafort Blanco, Miquel
Abad-Cardiel, M.
Martín-Rioboo, E.
Morales-Olivas, F.
Vinyoles, E.
Armario, P.
Banegas Banegas, José Ramón
Coca, A.
Sierra, Alejandro de la
Martell-Claros, N.
Redón, J.
Ruilope, L.M.
Segura, J.
Keywords: Pressió sanguínia
Malalties cardiovasculars
Hipotensió arterial
Blood pressure
Cardiovascular diseases
Hypotension
Issue Date: 23-Apr-2018
Publisher: Elsevier
Abstract: The American College of Cardiology (ACC) and the American Heart Association (AHA) have recently published their guidelines for the prevention, detection, evaluation, and management of hypertension in adults. The most controversial issue is the classification threshold at 130/80 mmHg, which will allow a large number of patients to be diagnosed as hypertensive who were previously considered normotensive. Blood pressure (BP) is considered normal (<120 mmHg systolic and <80 mmHg diastolic), elevated (120-129 and <80 mmHg), stage 1 (130-139 or 80-89 mmHg), and stage 2 (≥140 or ≥90 mmHg). Out-of-office BP measurements are recommended to confirm the diagnosis of hypertension and for titration of BP-lowering medication. In management, cardiovascular risk would be determinant since those with grade 1 hypertension and an estimated 10-year risk of atherosclerotic cardiovascular disease ≥10%, and those with cardiovascular disease, chronic kidney disease and/or diabetes will require pharmacological treatment, the rest being susceptible to non-pharmacological treatment up to the 140/90 mmHg threshold. These recommendations would allow patients with level 1 hypertension and high atherosclerotic cardiovascular disease to benefit from pharmacological therapies and all patients could also benefit from improved non-pharmacological therapies. However, this approach should be cautious because inadequate BP measurement and/or lack of systematic atherosclerotic cardiovascular disease calculation could lead to overestimation in diagnosing hypertension and to overtreatment. Guidelines are recommendations, not impositions, and the management of hypertension should be individualized, based on clinical decisions, preferences of the patients, and an adequate balance between benefits and risks.
Note: Reproducció del document publicat a: https://doi.org/10.1016/j.hipert.2018.04.001
It is part of: Hipertensión y Riesgo Vascular, 2018, vol. 35, num. 3, p. 119-129
URI: http://hdl.handle.net/2445/172293
Related resource: https://doi.org/10.1016/j.hipert.2018.04.001
ISSN: 1889-1837
Appears in Collections:Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
680271.pdf964.13 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons